期刊文献+

上海地区早发性乳腺癌临床病理特征分析 被引量:11

Clinicopathological Features of Early-onset Breast Cancer Patients in Shanghai
下载PDF
导出
摘要 目的根据乳腺癌在我国早发的特点,分析上海地区早发性乳腺癌患者相关的重要临床病理学参数。方法研究对象为来自2000年后就诊长海医院和瑞金医院的乳腺癌患者,将发病年龄小于35岁定义为早发性乳腺癌,分析肿瘤大小、腋窝淋巴结转移数目、AJCC分期、组织学分级、ER和PR表达情况,Her-2表达情况以及分子分型、2009年St.Gallen乳腺癌专家共识分型之间的关系。结果通过分析后发现Her-2、肿瘤大小、组织学分级、分子分型(基底细胞样乳腺癌和管腔型B乳腺癌)、ER*PR共表达(ER+/PR-和ER-/PR+)与上海地区早发性乳腺癌(发病年龄<35岁时)关系密切。结论上海地区<35岁发病的早发性乳腺癌与发病年龄晚的乳腺癌不同,早发性乳腺癌组织学3级居多,ER/PR阳性率低与三阴乳腺癌和和管腔型B乳腺癌关系密切。 Abstract Objective The clinicopathological features of early - onset breast cancer in Shanghai were studied owing to earlier age at diagnosis in China. Methods We analyzed 2232 cases with invasive breast cancer in Changhai Hospital and Ruijin Hospital in Shanghai. Patients having breast cancers before 35 years were defined as early - onset breast cancers. The association between early - onset breas! cancer and other elinieopathologieal factors including tumor size, lymph node metastasis, AJCC stage, histologic grade, expression of ER, PR and Her- 2, molecular subtypes and international expert consensus on the primary therapy of early breast cancer in 2009 was ana- lyzed. Results The early - onset breast cancer was more likely to be high histologie grade, basal - like phenotype, luminal - B pheno- type and neither of ER/PR expression. Conclusion The early - onset breast cancer in Shanghai was characterized by higher histologic grade and more likely to be either basal - like or luminal - B phenotype and absent hormonal receptor expression.
出处 《医学研究杂志》 2011年第5期36-40,共5页 Journal of Medical Research
基金 国家自然科学基金资助项目(81072175) 上海市卫生局科研项目(2009113) 上海市重点学科建设项目(B905)
关键词 雌激素受体 孕激素受体 HER2/NEU 早发性乳腺癌 Estrogen receptor Progesterone receptor Her - 2/neu Early - onset breast cancer
  • 相关文献

参考文献1

二级参考文献25

  • 1Ross JS, Linette GP, Stec J, et al. Breast cancer biomarkers and molecular medicine: part Ⅱ. Expert Rev Mol Diagn, 2004, 4: 169-188.
  • 2Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist, 2004, 9: 606-616.
  • 3Stefansson S, McMahon GA, Petitclerc E, et al. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des, 2003, 9: 1545-1564.
  • 4Look MP, van Putten WL, Duffy M J, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAl-1 in 8377 breast cancer patients. J Natl Cancer Inst, 2002, 94: 116-128.
  • 5Janicke F, Prechtl A, Thomssen C, etal. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst, 2001, 93: 913-920.
  • 6Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res, 2000, 60: 636-643.
  • 7Hansen S, Overgaard J, Rose C, et al. Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients. Br J Cancer, 2003, 88: 102-108.
  • 8Sweep CG, Geurts-Moespot J, Grebenschikov N, et al. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAl-1) in human breast cancer tissue extracts. Br J Cancer. 1998.78: 1434-1441.
  • 9Ferrier CM, de Witte HH, Straatman H, et al. Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. Br J Cancer, 1999, 79: 1534-1541.
  • 10Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Stat Assoc, 1958, 53: 457-481.

共引文献1

同被引文献84

  • 1李洪林,冯晓莉,藤茂芳,张保宁,郝玉芝.触摸不清的乳腺病灶在超声引导下的粗针穿刺活检[J].中国超声医学杂志,2007,23(3):182-185. 被引量:11
  • 2周永昌,郭万学.超声医学[M]第4版(下册).北京:科学技术文献出版社,2002:1 383.
  • 3张缙熙,姜玉新.浅表器官及组织超声诊断学[M].北京:科学文献出版社,2006:130-140.
  • 4Anders CK,Hsu DS,Brodwater G,et al.Young age at diagnosis corre- lates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression [J].J Clin Oncol,2008,26 (20):3324-3330.
  • 5Rapiti E,Fioretta G,Verkooijen HM,et al.Survival of young and older breast cancer patients in Geneva from 1990 to 2001 [J].Eur J Cancer, 2005,41(10): 1446-1452.
  • 6Soon MS,Baker JA,Rosen EL.Sonography of solid breast lesion: observer variability of lesion description and assessment[J].AJR, 1999,172(6):1621-1625.
  • 7MA Maggard,JB O’Connell,KE Lane,JH Liu,DA Etzioni,CY Ko.Do young breast cancer patients have worse outcomes?Journal of Surgical Research,2003.
  • 8Liu M,Lawson G,Delos M,et al.Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis: comparison with clinical and radiologic examinationsHead and Neck Journal for the Sciences and Space of the Head and Neck,2003.
  • 9Tut VM,Braithwaite AL,Angus B,et al.Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67British Journal of Cancer,2001.
  • 10Niewiadomska H,Jeziorski A,Olborski B.The expression of the pro-liferating antigen Ki67,PCNAand products of suppressor gene p53in primary invasive ductal breast carcinomaJournal of Experimental and Clinical Cancer Research,1998.

引证文献11

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部